Transcriptional and immunohistological assessment of immune infiltration in pancreatic cancer.
Adenocarcinoma
/ genetics
Adult
Aged
Aged, 80 and over
Female
Gene Expression Profiling
/ methods
Gene Expression Regulation, Neoplastic
/ genetics
Humans
Lymphocytes, Tumor-Infiltrating
/ immunology
Male
Middle Aged
Pancreatic Neoplasms
/ genetics
Prospective Studies
T-Lymphocytes
/ immunology
Tumor Microenvironment
/ genetics
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
12
02
2020
accepted:
15
08
2020
entrez:
1
9
2020
pubmed:
1
9
2020
medline:
21
10
2020
Statut:
epublish
Résumé
Pancreatic adenocarcinoma is characterized by a complex tumor environment with a wide diversity of infiltrating stromal and immune cell types that impact the tumor response to conventional treatments. However, even in this poorly responsive tumor the extent of T cell infiltration as determined by quantitative immunohistology is a candidate prognostic factor for patient outcome. As such, even more comprehensive immunophenotyping of the tumor environment, such as immune cell type deconvolution via inference models based on gene expression profiling, holds significant promise. We hypothesized that RNA-Seq can provide a comprehensive alternative to quantitative immunohistology for immunophenotyping pancreatic cancer. We performed RNA-Seq on a prospective cohort of pancreatic tumor specimens and compared multiple approaches for gene expression-based immunophenotyping analysis compared to quantitative immunohistology. Our analyses demonstrated that while gene expression analyses provide additional information on the complexity of the tumor immune environment, they are limited in sensitivity by the low overall immune infiltrate in pancreatic cancer. As an alternative approach, we identified a set of genes that were enriched in highly T cell infiltrated pancreatic tumors, and demonstrate that these can identify patients with improved outcome in a reference population. These data demonstrate that the poor immune infiltrate in pancreatic cancer can present problems for analyses that use gene expression-based tools; however, there remains enormous potential in using these approaches to understand the relationships between diverse patterns of infiltrating cells and their impact on patient treatment outcomes.
Identifiants
pubmed: 32866185
doi: 10.1371/journal.pone.0238380
pii: PONE-D-20-04195
pmc: PMC7458344
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0238380Subventions
Organisme : NCI NIH HHS
ID : R01 CA182311
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA208644
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA244142
Pays : United States
Déclaration de conflit d'intérêts
I have read the journal’s policy and the authors of this manuscript have the following competing interests: MJG and MRC have research support from Bristol Myers Squibb, Mavupharma, and Jounce that is not relevant to the subject of this manuscript. Funding for this manuscript was provided by NIH R01CA182311 (MJG), NIH R01CA244142 (MJG), NIH R01CA208644 (MRC), and the Providence Opportunity Fund. The authors declare that these do not represent competing interests relevant to the subject of this manuscript.
Références
Elife. 2017 Nov 13;6:
pubmed: 29130882
Pancreas. 2017 Oct;46(9):1180-1187
pubmed: 28902789
F1000Res. 2014 Jul 01;3:146
pubmed: 25309732
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Nat Med. 2015 Aug;21(8):938-945
pubmed: 26193342
Trends Immunol. 2004 Dec;25(12):677-86
pubmed: 15530839
Pancreas. 2004 Jan;28(1):e26-31
pubmed: 14707745
Bioinformatics. 2003 Dec 12;19(18):2448-55
pubmed: 14668230
Nat Commun. 2018 Jun 20;9(1):2419
pubmed: 29925878
J Immunother. 2010 Oct;33(8):828-33
pubmed: 20842054
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Genome Biol. 2017 Nov 15;18(1):220
pubmed: 29141660
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Nat Immunol. 2019 Mar;20(3):326-336
pubmed: 30778252
Science. 2015 Dec 11;350(6266):1387-90
pubmed: 26516200
Clin Cancer Res. 2018 Aug 15;24(16):3813-3819
pubmed: 29739787
Cancer Res. 2009 Apr 1;69(7):3077-85
pubmed: 19293190
Genome Biol. 2014;15(12):550
pubmed: 25516281
JAMA Surg. 2018 Nov 1;153(11):1055-1057
pubmed: 30090929
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
Nature. 2016 Mar 3;531(7592):47-52
pubmed: 26909576
Cancer Res. 2013 Feb 1;73(3):1128-41
pubmed: 23221383
Immunity. 2018 Jul 17;49(1):178-193.e7
pubmed: 29958801
Nucleic Acids Res. 2015 Jul 1;43(W1):W566-70
pubmed: 25969447
J Immunol. 2003 Jan 1;170(1):270-8
pubmed: 12496409
Cancers (Basel). 2019 Jan 03;11(1):
pubmed: 30609853
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Curr Opin Immunol. 2006 Apr;18(2):206-13
pubmed: 16464564
Genome Biol. 2016 Oct 20;17(1):218
pubmed: 27765066
Trends Immunol. 2002 Nov;23(11):549-55
pubmed: 12401408
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Sci Rep. 2018 May 3;8(1):7012
pubmed: 29725089
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
Immunity. 2014 Feb 20;40(2):274-88
pubmed: 24530056
Nat Med. 2011 Apr;17(4):500-3
pubmed: 21460848
Methods Mol Biol. 2019;1913:13-31
pubmed: 30666596
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2796-801
pubmed: 21825174
Nat Methods. 2017 Apr;14(4):417-419
pubmed: 28263959
Cancer Res. 2004 Aug 15;64(16):5839-49
pubmed: 15313928
Biometrics. 2017 Sep;73(3):811-821
pubmed: 28099990